Major Depressive Disorder

The FDA approved esketamine (SPRAVATO) nasal spray as the first monotherapy for adults with TRD, showing rapid efficacy at 4 weeks.

A new study found that depression prevalence among older adults was greater for those who were 65 – 69 years old.

SP-624, a SIRT6 activator, showed promise in an exploratory study for treating depression and cognition in females with MDD. Positive EEG data suggests enhanced neural connectivity.

A recent study found individuals released from incarnation had a 10-fold greater prevalence of suicide mortality compared with the general population.

Although the oral navacaprant 80 mg failed to bring statistically significant improvements in depression symptoms, the study showed females respond better than males.

This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.

In a recent study, the prevalence of RLS occurred in 42.9% of participants with depression.

A study finds that therapists deliver high-quality CBT in routine psychiatric care but found no evidence that therapist adherence and competence correlate to patient outcomes.

America's mental health crisis continues to escalate—what drives it, and what lies ahead in 2025? Hear insight from psychiatry and psychology experts.

A study shows constipation has a causal relationship with schizophrenia and MDD, but the relationship with schizophrenia may have limited clinical implications.

A study found only 38% of patients in the large US academic health system screened for depression received antidepressants or mental health referrals.

A study found psilocybin therapy brings life-changing relief to depression symptoms triggered by clinicians’ frontline work during the COVID-19 pandemic.

A study revealed that people who are older, uneducated, unemployed, below the poverty line, publicly insured, rural, and male did not increase in psychotherapy use from 2018 to 2021.

Intra-Cellular Therapies announced they submitted a supplemental New Drug Application to the FDA for lumateperone (CAPLYTA) as an adjunctive therapy to antidepressants for MDD.

In part 1 of this 2-part discussion, hosts explore the ethical foundation and background of euthanasia and medically-assisted suicide.

In a recent phase 2a trial, SPN-820, a novel intracellular moderator of mTORC1, decreased suicidal ideation by 80%.

Alto Neuroscience's ALTO-100 failed to beat placebo in a phase 2b trial for depression, leading to a 60% stock drop.

In the complete response letter, the FDA classified deficiencies in the Abbreviated New Drug Application for ketamine as MINOR.

A study found that adding depression to Life's Essential 8 provides minimal improvements in predicting cardiovascular and all-cause mortality risk.

A new meta-analysis found elevated triglyceride levels in patients with major depressive disorder, potentially explaining the link between depression and cardiovascular risks.

A recent study shows the FDA's black-box warnings on antidepressants have led to decreased usage among youth, with an increase in suicide attempts and deaths observed.

A new study finds causal links between schizophrenia and MDD on IBS, highlighting the need for integrated care addressing both psychiatric and gastrointestinal symptoms.

Inpatients receiving brief cognitive behavioral therapy had a 60% reduced likelihood of suicide attempts and a 71% reduced rate of psychiatric readmissions post-discharge.

A report shows only 24%, 56%, and 62% of patients meet the criteria PSIL-AT for depression according to low-bound, mid-range, and upper-bound estimates, respectively.

A phase 3 trial found mirtazapine ineffective in reducing breathlessness in respiratory disease patients, urging caution with off-label antidepressant use.